Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations
Stock prices for Novo Nordisk dropped precipitously Friday after a last-minute announcement from the Biden administration that the premier drugs from the Danish pharmaceutical juggernaut have been selected for forced price negotiations for Medicare.
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.
Ozempic, Wegovy and Other Drugs Are Among 15 Selected for Medicare's Price Negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
1d
on MSN
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
2h
on MSN
Why Did Novo Nordisk (NVO) Go Down on Friday?
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
3d
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
1d
on MSN
Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats
Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...
1d
Novo Nordisk Unusual Options Activity
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
2d
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
1d
Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
12d
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
Morningstar
2d
Novo Nordisk AS ADR
We sell different types of
products
and services to both investment professionals and individual investors. These
products
and services are usually sold through license agreements or subscriptions ...
1d
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback